The purpose of this study was to estimate the fetal radiation exposure resulting from \(^{18}\text{F}-\text{FDG}\) PET procedures performed in pregnant patients with malignancies. **Methods:** Five pregnant patients with a biopsy-proven diagnosis of malignancy who underwent \(^{18}\text{F}-\text{FDG}\) PET studies were retrospectively reviewed. All patients underwent PET-only studies (and not PET/CT studies) with a reduced \(^{18}\text{F}-\text{FDG}\) dose (except for 1 patient who had a negative pregnancy test immediately before the \(^{18}\text{F}-\text{FDG}\) PET procedure but was confirmed to be pregnant a few weeks later), including vigorous hydration and diuresis to minimize radiation exposure to the fetus. One patient underwent \(^{18}\text{F}-\text{FDG}\) PET twice during her pregnancy (in the second and third trimesters). Fetal radiation dose was independently assessed for each patient, and an analysis was made of fetal radiation doses using the measurements of activity in the fetuses at various stages of pregnancy. **Results:** Six \(^{18}\text{F}-\text{FDG}\) PET studies in 5 pregnant patients were analyzed. The \(^{18}\text{F}-\text{FDG}\) PET scans were obtained in early pregnancy (n = 1), the second trimester (n = 2), and the third trimester (n = 3). The fetal dose exposure from \(^{18}\text{F}-\text{FDG}\) PET studies was estimated to range from 1.1 to 2.43 mGy for various trimesters in pregnancy (except for the patient in the early stage of pregnancy, in whom activity in the whole uterus was considered, and the fetal dose was estimated to be 9.04 mGy). All patients delivered healthy infants with no visible abnormalities at term. **Conclusion:** The fetal radiation dose from \(^{18}\text{F}-\text{FDG}\) PET studies is quite low and significantly below the threshold dose for deterministic effects due to radiation exposure to the fetus. The estimated fetal radiation exposure in our cases was slightly lower than existing estimates on fetal dose exposure, and as more data become available, the current fetal dose estimates may have to be modified accordingly. By addressing an important safety issue dealing with performing medically necessary \(^{18}\text{F}-\text{FDG}\) PET in pregnant patients, these data are expected to help in the imaging workup of cancer patients during pregnancy.

**Key Words:** PET; radiation safety; \(^{18}\text{F}-\text{FDG}\) PET; fetal radiation dose


DOI: 10.2967/jnumed.110.085381
the risks and benefits of $^{18}$F-FDG PET in diseased pregnant patients combined with medical liability concerns may result in a conservative and potentially inappropriate choice to withhold necessary medical imaging in such situations. The purpose of this article is to document our successful experiences with $^{18}$F-FDG PET in pregnant patients and to attempt to assess the fetal radiation exposure resulting from $^{18}$F-FDG PET procedures.

**MATERIALS AND METHODS**

Five pregnant patients referred to our PET center for oncologic $^{18}$F-FDG PET scans were included in this retrospective study. All 5 patients had a biopsy-proven diagnosis of cancer, and all, except for 1, had established pregnancy at the time of $^{18}$F-FDG PET. One patient was subsequently found to be pregnant a few weeks after her $^{18}$F-FDG PET scan, even though she had a negative urine pregnancy test immediately before her $^{18}$F-FDG PET procedure. All patients with confirmed pregnancy were counseled about the need for PET given their diagnosis and about the risks and benefits of PET in their situation. Informed consent was obtained from all patients with confirmed pregnancy before PET. The patients with a confirmed pregnancy specifically underwent PET-only scans (and not PET/CT scans) and received a smaller dose of the radiotracer $^{18}$F-FDG ($173.9–340.4$ MBq [4.7–9.2 mCi]) instead of the dose used in our standard protocols ($555$ MBq [15 mCi]). The patient who tested negatively for pregnancy immediately before her imaging session received a dose of $583.12$ MBq (15.76 mCi) of all patients received oral (480–540 mL [16–18 oz]) water) and intravenous hydration (250 mL of 0.9% saline) during the $^{18}$F-FDG uptake period (~90 min) and underwent diuresis with furosemide (10 mg) administered intravenously 15 min after $^{18}$F-FDG administration. On average, these patients voided 4 times during the uptake period, beginning approximately 30 min after $^{18}$F-FDG administration. The PET-only images were acquired on an Advance scanner (GE Healthcare) or a Discovery LightSpeed-4 scanner in PET-only mode (GE Healthcare) operating in 2-dimensional mode with 5 min per bed position (5–6 bed positions on average). Attenuation correction was provided by a $^{68}$Ge rod source transmission scan. The PET data were processed with iterative reconstruction using the ordered-subset expectation maximization method, and all appropriate corrections were included. Hydration and diuresis are a routine part of our imaging protocol, with the goal of minimizing radiation dosage to the patient and eliminating urinary tract activity. The first assumption was evaluated using the SAAMII compartmental modeling code and introducing change conditions at these times for the bladder compartment. The adult female (nonpregnant) model was used to assign doses for patient 1, with no assignment of activity to the uterus, as per the footnote in Table 1. For the other patients, the time integrals in Table 1 were assigned to the fetus, with the 3-mo-pregnant model used for patient 2 and the 6-mo-pregnant model used for the other 3 patients.

**RESULTS**

The 5 pregnant patients ranged in age from 22 to 37 y and had cervical cancer (2 patients), lymphoma (2 patients), and lung cancer (1 patient). One patient underwent $^{18}$F-FDG PET in an early stage of her pregnancy (presumably within 6 wk of gestation because the urine pregnancy test was negative immediately before the $^{18}$F-FDG PET scan). One patient underwent $^{18}$F-FDG PET during the second trimester, and 2 patients underwent $^{18}$F-FDG PET during the third trimester of pregnancy. One patient underwent two $^{18}$F-FDG PET scans during pregnancy: 1 in the second trimester and 1 in the third trimester. In the patient who underwent $^{18}$F-FDG PET early during pregnancy, the fetus was not clearly visualized, and only diffusely increased $^{18}$F-FDG activity was noted in the uterus (Fig. 1). In all other patients, the fetus was clearly delineated with $^{18}$F-FDG uptake (Fig. 2), and in some cases, $^{18}$F-FDG activity was also noted in the fetal myocardium (Fig. 3), with mostly faint background $^{18}$F-FDG activity elsewhere in the remaining parts of the fetus. There was no prominent focal $^{18}$F-FDG uptake.

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time–activity integral (Bq·h/Bq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>0.21</td>
</tr>
<tr>
<td>Heart wall</td>
<td>0.11</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.079</td>
</tr>
<tr>
<td>Liver</td>
<td>0.13</td>
</tr>
<tr>
<td>Other tissues</td>
<td>1.7</td>
</tr>
</tbody>
</table>

An analysis was made of fetal doses using the measurements of activity in the fetuses at various stages of pregnancy and combined with data for the standard metabolism of $^{18}$F-FDG as provided by the International Commission on Radiological Protection (ICRP) in publication 106 ([10]). Table 1 depicts the time–activity integrals for various organs, as suggested in the ICRP publication 106 model for $^{18}$F-FDG.

These integrals were entered into the OLINDA/EXM software (version 1.1) ([11]). For the urinary bladder, 2 assumptions were evaluated, using the ICRP publication 106 model for urinary excretion: routine 2-h bladder voiding and bladder voiding at 45, 60, 75, and 90 min. The first assumption was evaluated using the standard bladder-voiding module in OLINDA/EXM. The second assumption was evaluated using the SAAMII compartmental modeling code and introducing change conditions at these times for the bladder compartment. The adult female (nonpregnant) model was used to assign doses for patient 1, with no assignment of activity to the uterus, as per the footnote in Table 1. For the other patients, the time integrals in Table 1 were assigned to the fetus, with the 3-mo-pregnant model used for patient 2 and the 6-mo-pregnant model used for the other 3 patients.
in other fetal regions in any patient. All patients delivered healthy infants with no visible abnormalities at term. The characteristics of the patients with the time-integrated activity are shown in Table 2.

The results of calculated fetal dose in our patients are summarized in Table 3. Patient 1 received more activity than the other patients and thus had the highest fetal doses. Because there was no assigned fetal uptake, the urinary bladder was important to the total fetal dose, and changes in bladder voiding had a notable effect. Similarly, for patient 2 the assigned fetal activity was low, and the difference in fetal dose calculated by the 2 different voiding models (standard voiding and nonstandard voiding) was the highest for all patients (44% difference, whereas for others the difference was about 20%–25%). For patient 5, the assigned fetal uptake was the highest, and the influence of bladder voiding was less pronounced (~11%). This radiation dose to the fetus represents activity from the administered radiopharmaceutical alone. Because all our studies were performed as PET-only studies with 68Ge rod source transmission scanning for attenuation correction, the additional radiation exposure from the transmission scanning was negligible (12,13) and was not included in the dose estimates. The observed uptake and time–activity integrals from this study are compared in Table 4 with those from 2 other studies, 1 by Stabin (14), assigned on the basis of observed activity measured in primates, and 1 by Zanotti-Fregonara et al. (15), measured in 1 human patient at about 10 wk of gestation. The values from Stabin are shown for the 3- and 6-mo cases, as were assigned to patients 2–6.

DISCUSSION

Medical imaging in pregnant patients is a delicate issue. Although radiopharmaceuticals have been administered to pregnant patients to perform nuclear medicine studies and there is literature about placental transfer of radiopharmaceuticals and dosimetry in pregnant patients (16) as well as about radiation-absorbed dose to the embryo or fetus from radiopharmaceuticals (17), these data lack information about fetal radiation exposure and dosimetry related to 18F-FDG PET. 18F-FDG PET was not in routine clinical use until the late 1990s and early 2000s. However, since then, 18F-FDG

FIGURE 1. Selected attenuation-corrected 18F-FDG PET images of 30-y-old woman with history of juvenile laryngeal papillomatosis and lung cancer. (A) Maximal-intensity-projection image in coronal projection showing intensely 18F-FDG–avid lesions in chest corresponding to lung cancer (solid arrow) and more modestly increased 18F-FDG activity in pelvis (dashed arrow). (B and C) Single sagittal and transaxial slices, respectively, showing that modestly increased pelvic 18F-FDG activity represents activity in expected region of uterus (arrows). This patient had negative pregnancy test immediately before 18F-FDG PET procedure but was confirmed to be pregnant 4 wk later, and hence increased 18F-FDG activity in uterus was attributed to early pregnancy.

FIGURE 2. Selected attenuation-corrected PET images from 18F-FDG PET study of 34-y-old woman, 28 wk pregnant and recently diagnosed with squamous cell carcinoma of cervix. (A) Maximal-intensity-projection image in coronal projection showing 18F-FDG activity (dashed arrow) related to fetus in pregnant uterus in lower abdomen and pelvis. (B) Two rows of selected coronal images showing 18F-FDG activity related to fetus in pregnant uterus in lower abdomen and pelvis (arrow). (C) Maximal-intensity-projection image in sagittal projection showing intense 18F-FDG uptake (arrow) in cervical malignancy posterior to urinary bladder activity.
PET has become an established imaging modality for evaluation of several malignancies, and it was estimated that more than 4 million 18F-FDG PET studies would be performed in 2010. Despite this, 18F-FDG PET studies of pregnant patients are extremely uncommon, and reports of even accidental 18F-FDG PET studies of pregnant patients are rare (15,18–21). Because adequate and accurate data regarding 18F-FDG uptake by the fetus are not available (other than the few case reports of accidental exposure), it is difficult to accurately calculate the fetal radiation exposure from 18F-FDG PET in pregnant patients. The existing estimates for fetal dose from 18F-FDG PET are mostly based on data from nonhuman primates and mathematic models (14,16,17,22). Recent case reports by Zanotti-Fregonara et al. (15,19) have raised the possibility that 18F-FDG dose to the fetus in early pregnancy may be higher than estimated by current dosimetric standards. Hence, there is a need to have more data to establish the accurate fetal dose exposure from 18F-FDG PET studies.

To our knowledge, this is the first and largest series of pregnant patients for whom fetal radiation exposure from 18F-FDG PET was calculated. Our data add considerably to the existing literature about fetal radiation exposure from 18F-FDG PET studies of pregnant patients. Moreover, our patients (except for 1) were not accidentally exposed to 18F-FDG during their pregnancy but rather underwent intentional studies that were performed after adequate consideration of the risks and benefits of 18F-FDG PET in these pregnant patients with malignancy. 18F-FDG is known to cross the placental membrane and accumulate in the fetus (15,18,19,22–24), and in all patients except 1, we were able to clearly identify 18F-FDG activity in the fetus inside the gravid uterus, confirming the ability of 18F-FDG to cross the placenta and accumulate in the fetus. The exception was the patient in the early stage of pregnancy, in whom we did see diffusely increased 18F-FDG activity in the uterus but not a clearly identifiable fetus. At that early stage, fetal morphology was not clearly delineated, and the activity probably represented uptake in the gestational sac and the uterus itself. Because these were stand-alone PET studies with transmission scanning for attenuation correction and not PET/CT studies, the anatomic details of various maternal regions including the intraembryonic fetus were not available from these 18F-FDG PET studies. However, we did see increased 18F-FDG activity in the fetal myocardial region in a few cases, as has also been documented in the past (21), with just faint background 18F-FDG activity elsewhere in the remaining fetal regions. There is no scientific literature documenting fetal toxicity associated with 18F-FDG in pregnant women or nonhuman primates. All of our patients delivered healthy babies at term.

**TABLE 2**

Characteristics of Pregnant Patients with Observed Fetal Concentrations and Time-Integrated Activity

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (y)</th>
<th>Weight (kg)</th>
<th>Administered activity (MBq)</th>
<th>Stage of gestation</th>
<th>Average observed concentration in fetus (kBq/mL)</th>
<th>Volume (cm³)</th>
<th>Fraction</th>
<th>Time-integrated activity (Bq-h/Bq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>30</td>
<td>67.6</td>
<td>583</td>
<td>–6 wk</td>
<td>16.8</td>
<td>124.1*</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>27</td>
<td>87.8</td>
<td>200</td>
<td>18 wk</td>
<td>1.98</td>
<td>86.9</td>
<td>0.00086</td>
<td>0.0023</td>
</tr>
<tr>
<td>3</td>
<td>22</td>
<td>67.1</td>
<td>337</td>
<td>25 wk</td>
<td>3.96</td>
<td>717</td>
<td>0.0084</td>
<td>0.0223</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>81.8</td>
<td>174</td>
<td>28 wk</td>
<td>2.31</td>
<td>535</td>
<td>0.0071</td>
<td>0.0187</td>
</tr>
<tr>
<td>5</td>
<td>27</td>
<td>88.6</td>
<td>229</td>
<td>30 wk</td>
<td>2.86</td>
<td>1,573</td>
<td>0.0196</td>
<td>0.0516</td>
</tr>
<tr>
<td>6</td>
<td>37</td>
<td>58.9</td>
<td>181</td>
<td>23 wk</td>
<td>2.56</td>
<td>552</td>
<td>0.0078</td>
<td>0.0206</td>
</tr>
</tbody>
</table>

*Only diffusely increased uptake in uterus was seen. Patients 2 and 5 are same patient (scanned twice during pregnancy).
The fetal volumes estimated by our methodology correlate well with the expected fetal volumes for that gestational age based on prior published MRI and ultrasound studies (9). Our results confirm that the fetal dose exposure from 18F-FDG PET studies is low and generally ranges from 1.1 to 2.43 mGy for various trimesters in pregnancy. This fetal dose exposure is significantly below the threshold dose for deterministic effects due to radiation exposure to the fetus. That threshold was postulated to be on the order of 100–600 mGy in the study of Steenvoorde et al. (25). There is no threshold for stochastic effects, but a discussion about the probability of various deterministic and stochastic effects occurring as a result of fetal exposure to radiation from 18F-FDG PET in pregnancy is beyond the scope of this article. The outlier in our data was the patient in the early stage of pregnancy, in whom we were unable to clearly delineate the fetus and instead considered the activity in the whole uterus. In this patient, the estimated total dose of 9.04 mGy is probably significantly overestimated because of technical factors but still remains well below the threshold for deterministic effects. Moreover, there are probably no deterministic or stochastic effects with radiation exposure soon after conception (26), and the threshold dose for deterministic effects is higher during the early pregnancy or embryonic period (27). More importantly, our calculations for fetal dose show that estimated fetal radiation exposure may in fact be slightly lower than existing estimates on fetal dose exposure (14,16,17) and the more recent values calculated by Zanotti-Fregonara et al. (15,19).

Our standard protocol for 18F-FDG PET studies also includes procedures such as adequate hydration in the form of oral water (when tolerated by the patient) and intravenous normal saline infusion (unless contraindicated medically), as well as vigorous diuresis using intravenous furosemide (also unless contraindicated medically) 15 min after 18F-FDG administration. These measures decrease the overall radiation exposure to the patient by more rapidly flushing the radiopharmaceutical from the body and at the same time improve the quality of images by decreasing background 18F-FDG activity. When an 18F-FDG PET scan is requested for a pregnant patient, we discuss the case with our referring clinical colleagues and after mutually determining that the study benefits indeed outweigh the risks, we counsel the patient and obtain informed consent before proceeding with the study. Our protocol for 18F-FDG PET in pregnant patients includes a few additional procedures to minimize radiation exposure to the fetus. We administer a lower dose of 18F-FDG to pregnant (555 MBq [15 mCi]) patients. In addition, we do not use a PET/CT technique in these patients because the CT component adds additional radiation exposure (estimated to range from 6 to 14 mGy (15,19,28,29), and depending on the CT protocol used) to the patient and the fetus. We used transmission scanning with a 68Ge rod source for attenuation correction in lieu of CT. Although our Advance Scanner is no longer operational, our Discovery LightSpeed-4 PET/CT scanners have the ability to operate in PET-only mode and use transmission scanning with a 68Ge rod source.
for attenuation correction in lieu of CT. This ability facilitates further reduction in the fetal radiation exposure from $^{18}$F-FDG PET in pregnant patients because the radiation dose from a $^{68}$Ge rod source is negligible ($12,13$). Although the exact values of fetal radiation dose from transmission scanning with a $^{68}$Ge rod source have not been calculated, for comparative purposes the effective dose from this method of scanning for cardiac and brain transmission studies has been estimated to be approximately 0.00077 and 0.00027 mSv/MBq-h, respectively. Hence, we have appropriately neglected this minimal amount of additional radiation exposure from the transmission scanning in our calculations. Moreover, using PET-only scanning, we were able to reduce the fetal radiation exposure by about 6–14 mGy when compared with PET/CT. $^{18}$F-FDG is excreted by the kidneys and is present in the urine in the urinary bladder ($30$). The anatomic position of the bladder with respect to the fetus renders it a primary source of radiation, and rapid elimination of the radioactive urine in the urinary bladder can facilitate minimizing fetal radiation exposure. Urinary bladder catheterization can reduce the amount of radioactive urine in the urinary bladder by continuously draining the urinary bladder and thus potentially help in decreasing fetal radiation exposure. However, vigorous hydration and diuresis also help in rapidly eliminating the radiopharmaceutical from the body (including the urinary bladder), and, along with the additional procedures implemented in our protocol for pregnant patients, helped keep the estimated fetal radiation doses from our $^{18}$F-FDG PET studies quite low and potentially safe.

CONCLUSION
Our data indicate that the fetal radiation exposure from $^{18}$F-FDG PET performed, when medically necessary, in pregnant women with cancer is low. However, all efforts should be made to minimize the fetal radiation exposure by modifying the protocol appropriately. The estimated fetal radiation dose calculated in our setting is low, and as more data become available, the current fetal dose estimates may require further modification.

DISCLOSURE STATEMENT
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

ACKNOWLEDGMENT
No potential conflict of interest relevant to this article was reported.

REFERENCES